Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2011:7:313-7.
doi: 10.2147/NDT.S19239. Epub 2011 Jun 15.

Cost-effectiveness analysis of memantine for moderate-to-severe Alzheimer's disease in the Netherlands

Bart Hoogveldt  1 , Benoît Rive, Johan Severens, Khaled Maman, Chantal Guilhaume
Affiliations

Cost-effectiveness analysis of memantine for moderate-to-severe Alzheimer's disease in the Netherlands

Bart Hoogveldt et al. Neuropsychiatr Dis Treat. 2011.

Abstract

Objective: The purpose of this study was to estimate the cost-effectiveness of memantine relative to standard care in patients with moderate-to-severe Alzheimer's disease in the Netherlands.

Methods: A country-adapted five-year Markov model simulated disease progression through a series of states, defined by dependency and disease severity. Transition probabilities were derived from trials, with utility and epidemiological data obtained from a longitudinal Dutch cohort. Cost-effectiveness was described in terms of quality-adjusted life years and time spent in a nondependent state or in a moderate severity state.

Results: Memantine monotherapy versus standard care led to 0.058 quality-adjusted life years gained (1.207 versus 1.265), longer time in a nondependent state (from 1.602 to 1.751 years) and in a moderate state (from 2.051 to 2.141 years), and no additional costs (€113,927 versus €110,097). Robustness of results was confirmed through sensitivity analyses.

Conclusion: Memantine is dominant compared with standard care in the Netherlands. Results are consistent with similar economic evaluations in other countries.

Keywords: Alzheimer’s disease; Netherlands; cholinesterase inhibitors; cost-effectiveness analysis; memantine.

PubMed Disclaimer

References

    1. Perenboom RJ, Boshuizen HC, Breteler MM, Ott A, Van de Water HP. Dementia-free life expectancy (DemFLE) in The Netherlands. Soc Sci Med. 1996;43:1703–1707. - PubMed
    1. Caro JJ, Salas M, Ward A, Getsios D, Mehnert A. Economic analysis of galantamine, a cholinesterase inhibitor, in the treatment of patients with mild to moderate Alzheimer’s disease in the Netherlands. Dement Geriatr Cogn Disord. 2002;14:84–89. - PubMed
    1. McDonnell J, Redekop WK, Van der Roer N, et al. The cost of treatment of Alzheimer’s disease in The Netherlands: A regression-based simulation model. Pharmacoeconomics. 2001;19:379–390. - PubMed
    1. Gagnon M, Rive B, Hux M, Guilhaume C. Cost-effectiveness of memantine compared with standard care in moderate-to-severe Alzheimer disease in Canada. Can J Psychiatry. 2007;52:519–526. - PubMed
    1. College voor Zorgverzekeringen. Guidelines for Pharmacoeconomic Research, Updated Version. Diemen, The Netherlands: College voor Zorgverzekeringen; 2006.